Trials / Not Yet Recruiting
Not Yet RecruitingNCT07402070
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
A Phase II Study Evaluating the Efficacy and Safety of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI363 | Subjects will receive IBI363 for up to 4 cycles, each cycle is 21 days, the first treatment cycle is 28 days |
Timeline
- Start date
- 2026-02-04
- Primary completion
- 2026-12-31
- Completion
- 2030-12-31
- First posted
- 2026-02-11
- Last updated
- 2026-02-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07402070. Inclusion in this directory is not an endorsement.